Threat actors abused trusted Trivy distribution channels to inject credential‑stealing malware into CI/CD pipelines worldwide ...

Amazon has agreed to pay $2.5 billion to settle allegations brought by the Federal Trade Commission over how it enrolled customers in Prime and how difficult it made cancellation. The FTC alleged ...

Ricursive Intelligence, a startup building an AI system to design and automatically improve AI chips, has raised $300 million at a $4 billion valuation. The company said Monday the round was led by ...

Amazon customers can file a claim to receive a refund for their Prime subscriptions as part of the company's $2.5 billion settlement with the Federal Trade Commission over allegations of deceptive ...

Amazon customers can now file a claim under its $2.5 billion settlement with the Federal Trade Commission, which resolved allegations of deceptive enrollment practices in the retailer's Prime shopping ...

(NEXSTAR) – The second phase of a $2.5 billion settlement over Amazon Prime has begun, giving those who have not yet received a payment a chance to cash in. Last year, Amazon settled with the Federal ...

To kick off 2026, Amazon Prime members will be able to download 10 more free games starting this month. Over a dozen separate games will be able to stream via Luna cloud delivery as well. Civilization ...

Michael Block is a 14 time GLAM Award nominated writer, producer, and host of the podcast Block Talk. Throughout his time in the entertainment industry, he has worked on and off Broadway as a stage ...

Prime Video is one of those streamers that we're lucky to get one decent option from each month, but in December we're getting one of its best. Season 2 of the post-apocalyptic drama-comedy Fallout is ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...